Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Adding an invasive procedure will not necessarily change treatment or outcome of NSCLC patients with preoperative clinical N1 disease

Alfredo Addeo, Giuseppe Banna
European Respiratory Journal 2018 51: 1800084; DOI: 10.1183/13993003.00084-2018
Alfredo Addeo
1Oncology Dept, University Hospital Geneva, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: alfredo.addeo@hcuge.ch
Giuseppe Banna
2Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Video-assisted mediastinoscopy or VAM-lymphadenectomy is not a standard procedure in cN1 disease http://ow.ly/dAZq30irs63

To the Editor:

We have read with great interest and welcome the publication of a prospective multicentre study regarding the role of mediastinal staging by video-assisted mediastinoscopy (VAM) in patients with clinical N1 (cN1) nonsmall cell lung cancer (NSCLC) [1]. The objective of the study was to assess the sensitivity, negative predictive value and accuracy of VAM in a well-defined group of patients with cN1.

This nonrandomised prospective study planned to recruit 250 NSCLC patients with stage cT1-3N1M0 deemed operable based on integrated fluorodeoxyglucose-positron-emission tomography/computed tomography. The surgical resection with systemic nodal dissection was the reference standard. The primary end-point was sensitivity, defined as the proportion of patients with positive mediastinal staging by VAM or VAM-lymphadenectomy (VAMLA) out of all the patients with mediastinal nodal disease.

The authors concluded that 25% of the patients within the study eventually had unsuspected N2 disease with a 73% sensitivity by VAM and proposed the procedure as a possible standard of care in this setting.

As conceived by the authors, there are several limitations in this study, two particularly important and worth mentioning further. The first regards the slow and inadequate recruitment leading to only 105 patients being enrolled into the study instead of the pre-planned 250 patients. The second point is the fact that in nearly one-third (31%) of cases the nodal dissection was performed by VAMLA and not only by VAM. Although similar, the two procedures are different: during VAMLA a systematic lymphadenectomy is performed bi-manually through the video mediastinoscope and the number of lymph nodes removed is doubled compared to standard mediastinoscopy [2].

Although these two issues do not allow us to conclude that VAM(LA) could be a new standard in cN1 NSCLC patients, another point regards the real implication of routinely performing VAM(LA) in this setting. Even if this is recommended within the guidelines of the European Society of Thoracic Surgeons [3], the level of evidence is certainly not that strong (level IIB) and unlikely to change the outcome or treatment of such patients. There is also evidence that patients with unsuspected N2 disease have a better overall survival than those with standard N2 nodal disease [4] and that those with single-station N2 involvement have similar overall survival than those with multiple N1 disease, as established recently [5].

In conclusion, we should certainly praise the authors for making such an effort to design and conduct a multicentre prospective study; however, we believe that there is not adequate evidence to justify VAM(LA) as a standard tool to adopt in all cN1 NSCLC patients preoperatively.

Footnotes

  • Conflict of interest: None declared.

  • Received January 15, 2018.
  • Accepted January 23, 2018.
  • Copyright ©ERS 2018

References

  1. ↵
    1. Decaluwé H,
    2. Dooms C,
    3. D'Journo XB, et al.
    Mediastinal staging by videomediastinoscopy in clinical N1 non-small cell lung cancer: a prospective multicentre study. Eur Respir J 2017; 50: 1701493.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Leschber G,
    2. Holinka G,
    3. Linder A
    . Video-assisted mediastinoscopic lymphadenectomy (VAMLA) – a method for systematic mediastinal lymphnode dissection. Eur J Cardiothorac Surg 2003; 24: 192–195.
    OpenUrlCrossRefPubMed
  3. ↵
    1. De Leyn P,
    2. Dooms C,
    3. Kuzdzal J, et al.
    Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg 2014; 45: 787–798.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Thomas DC,
    2. Arnold BN,
    3. Rosen JE, et al.
    The significance of upfront knowledge of N2 disease in non-small cell lung cancer. World J Surg 2018; 42: 161–171.
    OpenUrl
  5. ↵
    1. Asamura H,
    2. Chansky K,
    3. Crowley J, et al.
    The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2015; 10: 1675–1684.
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 51 Issue 4 Table of Contents
European Respiratory Journal: 51 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Adding an invasive procedure will not necessarily change treatment or outcome of NSCLC patients with preoperative clinical N1 disease
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Adding an invasive procedure will not necessarily change treatment or outcome of NSCLC patients with preoperative clinical N1 disease
Alfredo Addeo, Giuseppe Banna
European Respiratory Journal Apr 2018, 51 (4) 1800084; DOI: 10.1183/13993003.00084-2018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Adding an invasive procedure will not necessarily change treatment or outcome of NSCLC patients with preoperative clinical N1 disease
Alfredo Addeo, Giuseppe Banna
European Respiratory Journal Apr 2018, 51 (4) 1800084; DOI: 10.1183/13993003.00084-2018
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Agora

Correspondence

  • Clinical outcomes of bronchiectasis in India
  • Reply: Clinical outcomes of bronchiectasis in India
  • Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society